(NASDAQ: OCGN) Ocugen's forecast annual revenue growth rate of 366.63% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.55%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.46%.
Ocugen's revenue in 2026 is $4,413,000.On average, 7 Wall Street analysts forecast OCGN's revenue for 2026 to be $1,030,253,304, with the lowest OCGN revenue forecast at $0, and the highest OCGN revenue forecast at $2,065,752,965. On average, 4 Wall Street analysts forecast OCGN's revenue for 2027 to be $43,672,640,854, with the lowest OCGN revenue forecast at $32,655,291,709, and the highest OCGN revenue forecast at $54,929,355,026.
In 2028, OCGN is forecast to generate $157,653,019,917 in revenue, with the lowest revenue forecast at $97,985,548,964 and the highest revenue forecast at $212,788,950,239.